Mangalam Drugs & Organics
29.70
-0.50(-1.66%)
Market Cap₹47.01 Cr
PE Ratio-1.52
IndustryHealthcare
Company Performance:
1D-1.66%
1M-6.19%
6M-60.99%
1Y-62.93%
5Y-72.73%
View Company Insightsright
More news about Mangalam Drugs & Organics
07Jan 26
Mangalam Drugs & Organics Clarifies No Material Information Behind Recent Price Movement
Mangalam Drugs & Organics Limited responded to BSE surveillance regarding recent stock price movements, clarifying no material undisclosed information exists. The company attributed price fluctuations to market sentiment and confirmed timely disclosure of all material information as per regulatory requirements.
 no imag found
24Dec 25
Mangalam Drugs & Organics CFO Ajay Samant Resigns Upon Reaching Retirement Age
Mangalam Drugs & Organics Limited announced the resignation of CFO Mr. Ajay Samant, effective March 31, 2025, due to reaching retirement age per company guidelines. The resignation was tendered on March 28, 2025, and approved by the Board on March 29, 2025. The company initially missed disclosing the resignation reason but has now provided complete information to comply with SEBI LODR Regulations.
 no imag found
25Nov 25
Mangalam Drugs Secures Rs. 15 Crore Export Order for Anti-Malarial API
Mangalam Drugs & Organics Limited (MDOL) has received a repeat export order for Anti-Malarial Active Pharmaceutical Ingredient (API) from an international client. The order is valued at approximately Rs. 15 Crore and will be executed over the next 2-4 months. This development is expected to strengthen MDOL's position in the global pharmaceutical market, contribute to its growth trajectory, and enhance revenue visibility in the near term.
 no imag found
18Nov 25
Mangalam Drugs & Organics Defaults on Bank Loans Totaling Rs 765.19 Lacs
Mangalam Drugs & Organics Limited has defaulted on loan obligations totaling Rs 765.19 lacs to Bank of Maharashtra (Rs 414.93 lacs) and Bank of Baroda (Rs 350.26 lacs). The defaults began in October 2025 and have exceeded 30 days. The company attributes the financial stress to discontinued US Aid funding and reduced orders for TB, HIV, and Malaria treatments. Mangalam has requested loan restructuring and plans to submit a restructuring plan by mid-December 2025.
 no imag found
13Nov 25
Mangalam Drugs and Organics Reschedules Board Meeting to November 20, 2025
Mangalam Drugs & Organics Limited has postponed its Board of Directors meeting from November 13 to November 20, 2025. The meeting agenda includes approving Q3 2025 financial results and acknowledging the CFO's resignation. A trading window closure is in effect from October 1, 2025, until 48 hours after the results announcement.
 no imag found
15Oct 25
Mangalam Drugs and Organics Receives NCLT Approval for Merger Scheme
Mangalam Drugs & Organics Limited (MDOL) received an NCLT order admitting a petition for a merger scheme involving Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited. The petition was presented on September 23, 2025, with a final hearing scheduled for December 16, 2025. NCLT has directed notices to be issued to various statutory authorities, giving them 30 days to submit representations. MDOL will keep stock exchanges informed of further developments.
 no imag found
06Oct 25
Manglam Group Launches ₹100 Crore Redevelopment Project in Mumbai's Borivali
Manglam Group has launched its first redevelopment project in Mumbai, Manglam Rajanigandha, in Borivali (West) with a ₹100 crore investment. The project, expected to generate ₹150 crore in revenue, will offer 80 two-bedroom apartments across 80,000 sq. ft. Half of the units will be allocated to existing tenants. The development includes amenities like landscaped green zones, a fitness center, and a jogging track. Homeowners will receive lifetime membership at the Mandapeshwar Civic Federation Gymkhana. The project is set for completion in June 2026.
 no imag found
06Sept 25
Mangalam Drugs Shares Pledged by Shree Kishoriju Trading for Debt Security
Shree Kishoriju Trading and Investment Private Limited has pledged 877,000 shares (5.54%) of Mangalam Drugs & Organics Limited to Badjate Stock Broking Private Limited. This increases Shree Kishoriju's total encumbered holdings to 1,098,515 shares, representing 6.94% of the company's share capital. Director Radhika Ajay Dhoot disclosed this information to stock exchanges in compliance with regulations.
 no imag found
14Aug 25
Mangalam Drugs & Organics' Merger Scheme Receives Strong Backing from Unsecured Creditors
Mangalam Drugs & Organics Limited's proposed merger scheme gained overwhelming support from unsecured creditors at a Tribunal Convened Meeting. The scheme, involving the absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited, received 98.46% approval in value terms. Out of 80 eligible creditors, 36 participated, with 37 voting in favor and 1 against. The Board of Directors is now authorized to proceed with implementing the merger, subject to regulatory approvals.
 no imag found
Mangalam Drugs & Organics
29.70
-0.50
(-1.66%)
1 Year Returns:-62.93%
Industry Peers
Sun Pharmaceutical
1,763.20
(-0.78%)
Divis Laboratories
6,000.00
(-1.64%)
Torrent Pharmaceuticals
4,187.90
(-1.93%)
Dr Reddys Laboratories
1,276.00
(-1.76%)
Lupin
2,290.60
(-1.37%)
Cipla
1,243.70
(-1.01%)
Zydus Life Science
879.10
(-1.28%)
Mankind Pharma
1,937.40
(-3.13%)
Aurobindo Pharma
1,276.70
(-1.14%)
Alkem Laboratories
5,131.00
(-2.41%)